Did Sandoz’s Expanded Henlius Biosimilar Pact Just Redraw Its (SWX:SDZ) Investment Narrative?

• Sandoz Group AG recently announced a collaboration agreement with Shanghai Henlius Biotech, Inc. to develop, manufacture and commercialise up to 10 biosimilars, including proposed versions of cetuximab, evolocumab and belimumab, with Henlius handling development and manufacturing and Sandoz holding commercial rights outside China under a milestones-based deal of up to US$322 million.
• This partnership lifts Sandoz’s biosimilar pipeline from 39 assets with potential to reach up to 46, underscoring how external development alliances are becoming central to its effort to broaden access to complex biologic medicines worldwide.
• We’ll now examine how this expanded Henlius biosimilar collaboration, and the shift toward partnered development, might influence Sandoz’s broader investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Sandoz Group Investment Narrative Recap

To own Sandoz, you need to believe that a larger, partner-heavy biosimilar pipeline can offset pricing pressure in generics and biosimilars and support improving earnings. The Henlius deal strengthens the near and medium term catalyst of pipeline execution, but it also reinforces dependence on partnered assets, which could keep long term margins and control over key products as a central risk.

The recent half year 2026 results, with higher sales of US$5,761 million but a drop in net income to US$109 million, are highly relevant here. They highlight how execution on new launches and partnerships like Henlius may matter more for the earnings trajectory than topline growth alone, especially while pricing and regional exposure remain key swing factors for the story.

Yet, while the expanded Henlius pipeline looks reassuring, investors should also be aware of how rising global pricing and tariff pressures could still...

Read the full narrative on Sandoz Group (it's free!)

Sandoz Group's narrative projects $13.4 billion revenue and $1.9 billion earnings by 2029. This requires 6.3% yearly revenue growth and approximately a $1.0 billion earnings increase from $914.0 million today.

Uncover how Sandoz Group's forecasts yield a CHF70.74 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming only about US$13.5 billion of revenue and US$1.7 billion of earnings by 2029, which looks much more restrained than the consensus pipeline story and shows how differently you might weigh the new Henlius agreement versus growing global pricing and tariff risks.

Explore 4 other fair value estimates on Sandoz Group - why the stock might be worth just CHF70.74!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Sandoz Group research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Sandoz Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sandoz Group's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com